A bile acid-related prognostic signature in hepatocellular carcinoma

[1]  A. Majumdar,et al.  Gene expression based inference of cancer drug sensitivity , 2022, Nature Communications.

[2]  Md. Jamal Hossain,et al.  A Renewed Concept on the MAPK Signaling Pathway in Cancers: Polyphenols as a Choice of Therapeutics. , 2022, Pharmacological research.

[3]  D. Rozman,et al.  The role of bile acids in carcinogenesis , 2022, Cellular and Molecular Life Sciences.

[4]  Q. Gao,et al.  Changing epidemiology of hepatocellular carcinoma in Asia , 2022, Liver international : official journal of the International Association for the Study of the Liver.

[5]  Ping Wang,et al.  Identification of a novel immune-related long noncoding RNA signature to predict the prognosis of bladder cancer , 2022, Scientific Reports.

[6]  R. Cox,et al.  AKR1D1 knockout mice develop a sex-dependent metabolic phenotype , 2022, The Journal of endocrinology.

[7]  Tatyana V Butkova,et al.  A Recent Ten-Year Perspective: Bile Acid Metabolism and Signaling , 2022, Molecules.

[8]  Chieh-Hsin Lin,et al.  Fatty Acid Binding Protein 6 Inhibition Decreases Cell Cycle Progression, Migration and Autophagy in Bladder Cancers , 2022, International journal of molecular sciences.

[9]  Rohit Kohli,et al.  The Role of FGF19 and MALRD1 in Enterohepatic Bile Acid Signaling , 2022, Frontiers in Endocrinology.

[10]  M. Czaja,et al.  Redundant Functions of ERK1 and ERK2 Maintain Mouse Liver Homeostasis Through Down‐Regulation of Bile Acid Synthesis , 2021, Hepatology communications.

[11]  Xiaorui Hou,et al.  Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects , 2021, Frontiers in Immunology.

[12]  Ying Chen,et al.  Inhibition of FABP6 Reduces Tumor Cell Invasion and Angiogenesis through the Decrease in MMP-2 and VEGF in Human Glioblastoma Cells , 2021, Cells.

[13]  Wei Liu,et al.  Regulation Network and Prognostic Significance of Aldo-Keto Reductase (AKR) Superfamily Genes in Hepatocellular Carcinoma , 2021, Journal of hepatocellular carcinoma.

[14]  H. Huynh,et al.  Targeted inhibition of FGF19/FGFR cascade improves antitumor immunity and response rate in hepatocellular carcinoma , 2021, Hepatology International.

[15]  Shau-ku Huang,et al.  Phosphorylation of intestine-specific homeobox by ERK1 modulates oncogenic activity and sorafenib resistance. , 2021, Cancer letters.

[16]  D. Kleiner,et al.  Hepatocellular carcinoma as a complication of Niemann‐Pick disease type C1 , 2021, American journal of medical genetics. Part A.

[17]  Mengqin Yuan,et al.  Prognostic Implication of a Novel Metabolism-Related Gene Signature in Hepatocellular Carcinoma , 2021, Frontiers in Oncology.

[18]  Bingxin Li,et al.  Suppressing ERK Pathway Impairs Glycochenodeoxycholate-Mediated Survival and Drug-Resistance in Hepatocellular Carcinoma Cells , 2021, Frontiers in Oncology.

[19]  Yuan Liao,et al.  Diagnostic and prognostic values of AKR1C3 and AKR1D1 in hepatocellular carcinoma , 2021, Aging.

[20]  J. Nemunaitis,et al.  TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials , 2020, Cancer Gene Therapy.

[21]  Jean-David Fumet,et al.  Tumour mutational burden as a biomarker for immunotherapy: Current data and emerging concepts. , 2020, European journal of cancer.

[22]  T. Chan,et al.  Tumor mutational burden as a predictive biomarker for checkpoint inhibitor immunotherapy , 2019, Human vaccines & immunotherapeutics.

[23]  J. Storch,et al.  Fatty acid-binding proteins: functional understanding and diagnostic implications. , 2019, Current opinion in clinical nutrition and metabolic care.

[24]  Shanshan Liu,et al.  From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma , 2019, Journal of Experimental & Clinical Cancer Research.

[25]  J. Chiang,et al.  Bile Acids as Metabolic Regulators and Nutrient Sensors. , 2019, Annual review of nutrition.

[26]  Hua Tang,et al.  SLC27A5 deficiency activates NRF2/TXNRD1 pathway by increased lipid peroxidation in HCC , 2019, Cell Death & Differentiation.

[27]  M. van de Bunt,et al.  AKR1D1 is a novel regulator of metabolic phenotype in human hepatocytes and is dysregulated in non-alcoholic fatty liver disease , 2019, Metabolism: clinical and experimental.

[28]  Sung‐Min Ahn,et al.  FGF19–FGFR4 Signaling in Hepatocellular Carcinoma , 2019, Cells.

[29]  N. Nikolaou,et al.  AKR1D1 regulates glucocorticoid availability and glucocorticoid receptor activation in human hepatoma cells , 2019, The Journal of Steroid Biochemistry and Molecular Biology.

[30]  A. Stenzinger,et al.  Tumor mutational burden standardization initiatives: Recommendations for consistent tumor mutational burden assessment in clinical samples to guide immunotherapy treatment decisions , 2019, Genes, chromosomes & cancer.

[31]  A. Carino,et al.  Signaling from Intestine to the Host: How Bile Acids Regulate Intestinal and Liver Immunity. , 2019, Handbook of experimental pharmacology.

[32]  Yassen Assenov,et al.  Maftools: efficient and comprehensive analysis of somatic variants in cancer , 2018, Genome research.

[33]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[34]  Michele Biagioli,et al.  Bile Acids Activated Receptors Regulate Innate Immunity , 2018, Front. Immunol..

[35]  P. Schirmacher,et al.  EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. , 2018, Journal of hepatology.

[36]  M. Patterson,et al.  Consensus clinical management guidelines for Niemann-Pick disease type C , 2018, Orphanet Journal of Rare Diseases.

[37]  Wei Jia,et al.  Bile acid–microbiota crosstalk in gastrointestinal inflammation and carcinogenesis , 2018, Nature Reviews Gastroenterology & Hepatology.

[38]  E. Jaffee,et al.  Tumor Mutational Burden and Response Rate to PD-1 Inhibition. , 2017, The New England journal of medicine.

[39]  J. Boyer,et al.  Mechanisms of bile acid mediated inflammation in the liver. , 2017, Molecular aspects of medicine.

[40]  Levi Garraway,et al.  Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden , 2017, Genome Medicine.

[41]  Fengjie Huang,et al.  Dysregulated hepatic bile acids collaboratively promote liver carcinogenesis , 2016, International journal of cancer.

[42]  G. Blobel,et al.  Clues to the mechanism of cholesterol transfer from the structure of NPC1 middle lumenal domain bound to NPC2 , 2016, Proceedings of the National Academy of Sciences.

[43]  Minoru Kanehisa,et al.  KEGG as a reference resource for gene and protein annotation , 2015, Nucleic Acids Res..

[44]  G. Gores,et al.  Hepatocellular carcinoma , 2016, Nature Reviews Disease Primers.

[45]  Cheng-song Sun,et al.  Natural killer cell dysfunction in hepatocellular carcinoma and NK cell-based immunotherapy , 2015, Acta Pharmacologica Sinica.

[46]  Paul Geeleher,et al.  pRRophetic: An R Package for Prediction of Clinical Chemotherapeutic Response from Tumor Gene Expression Levels , 2014, PloS one.

[47]  N. Cox,et al.  Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines , 2014, Genome Biology.

[48]  A. Stahl,et al.  SLC27 fatty acid transport proteins. , 2013, Molecular aspects of medicine.

[49]  Hao Wu,et al.  Comparison of the Regulation of β-Catenin Signaling by Type I, Type II and Type III Interferons in Hepatocellular Carcinoma Cells , 2012, PloS one.

[50]  T. Penning,et al.  Characterization of Disease-related 5β-Reductase (AKR1D1) Mutations Reveals Their Potential to Cause Bile Acid Deficiency* , 2010, The Journal of Biological Chemistry.

[51]  W. Pan,et al.  Increased intratumoral regulatory T cells are related to intratumoral macrophages and poor prognosis in hepatocellular carcinoma patients , 2009, International journal of cancer.

[52]  S. Strom,et al.  Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7α‐hydroxylase gene expression , 2009, Hepatology.

[53]  Zheng Zhang,et al.  Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. , 2007, Gastroenterology.

[54]  Tatsuo Kanda,et al.  Fatty Acid Binding Protein 6 Is Overexpressed in Colorectal Cancer , 2006, Clinical Cancer Research.

[55]  P. Scambler,et al.  Mutations in SRD5B1 (AKR1D1), the gene encoding delta(4)-3-oxosteroid 5beta-reductase, in hepatitis and liver failure in infancy. , 2003, Gut.

[56]  M. Mareel,et al.  The role of bile acids in carcinogenesis. , 2001, Mutation research.

[57]  Susumu Goto,et al.  KEGG: Kyoto Encyclopedia of Genes and Genomes , 2000, Nucleic Acids Res..

[58]  N. Hayashi,et al.  Activation of mitogen‐activated protein kinases/extracellular signal‐regulated kinases in human hepatocellular carcinoma , 1998, Hepatology.

[59]  Supplemental Information 2: Kyoto Encyclopedia of genes and genomes. , 2022 .